ライフサイエンスコーパス: osteocalcin

1 proteoglycans, and matrix proteins, such as osteocalcin.

2 21days, and quantified by real time QPCR for osteocalcin.

3 amidation of a natural peptide derived from osteocalcin.

4 ers of osteogenesis alkaline phosphatase and osteocalcin.

5 ed serum levels of the bone formation marker osteocalcin.

6 activity of the insulin-sensitizing hormone osteocalcin.

7 promising bone resorption and bioactivity of osteocalcin.

8 and in humans by increasing the activity of osteocalcin.

9 ectly influenced by the bone-derived hormone osteocalcin.

10 re improved by infusion of undercarboxylated osteocalcin.

11 RUNX2, osterix, and the osteoblast protein, osteocalcin.

12 ine the carboxylation status and function of osteocalcin.

13 ting glucose metabolism through secretion of osteocalcin.

14 esponsible for decreasing the bioactivity of osteocalcin.

15 t marker genes such as bone sialoprotein and osteocalcin.

16 tomorphometry and real-time RT-PCR for human osteocalcin.

17 : type I collagen, alkaline phosphatase, and osteocalcin.

18 ased levels of insulin and undercarboxylated osteocalcin.

19 cular proteins in addition to collagen I and osteocalcin.

20 epatic tissues such as matrix Gla protein or osteocalcin.

21 d expression of Runx2 (3.5-fold, P<0.05) and osteocalcin (4-fold, P<0.05).

22 Here we show that osteocalcin, a bone-derived hormone, regulates beta-cell

23 rgy balance by stimulating the production of osteocalcin, a bone-derived protein that promotes insuli

24 netically forced expression of Runx2/p57 and osteocalcin, a classical bone-related target gene, under

25 Percentage of undercarboxylated osteocalcin, a functional measure of vitamin K status, w

26 ignificantly reduced tissue levels of aortic osteocalcin, a marker of mineralization.

27 rming osteoblasts and enhances production of osteocalcin, a secreted mediator of insulin sensitivity,

28 ody glucose homeostasis because it increases osteocalcin activity.

29 There were no significant changes in serum osteocalcin, albumin, and hemoglobin levels.

30 reased levels of core-binding factor alpha1, osteocalcin, alkaline phosphatase, and osteoprotegerin,

31 Removing one Osteocalcin allele from OST-PTP-deficient mice corrects

32 els of both insulin-like growth factor 1 and osteocalcin also were determined.

33 timulates bone cells to produce and activate osteocalcin, an endocrine hormone that increases the eff

34 from its ability to suppress the activity of osteocalcin, an osteoblast-derived hormone favoring gluc

35 a product that decreases the bioactivity of osteocalcin, an osteoblast-specific secreted molecule th

36 Osteocalcin and 17beta-estradiol mediate their effects t

37 ining the expression of bone-specific genes, osteocalcin and alkaline phosphatase as well as through

38 lls increased alkaline phosphatase activity, osteocalcin and alkaline phosphatase mRNA levels, and mi

39 Dlx5, and later of the bone marker proteins osteocalcin and alkaline phosphatase.

40 ble guanylyl cyclase inhibitor ODQ increased osteocalcin and alpha-smooth muscle actin expression.

41 Osteocalcin and bone morphogenic protein (BMP)-2 express

42 es for the Runx2 transcription factor in the osteocalcin and bone sialoprotein genes that cannot be r

43 decreased expression of osteoblast-specific osteocalcin and bone sialoprotein genes, alkaline phosph

44 Studies using wild-type and mutated osteocalcin and Bsp promoters revealed that Pbx1 acts th

45 Those in the lowest tertiles of total osteocalcin and carboxylated osteocalcin at baseline had

46 mined the association between 2-y changes in osteocalcin and changes in fasting glucose, insulin, HOM

47 ked surface-dependent increases in beta1 and osteocalcin and decreases in cell number and increases i

48 gy homeostasis via mechanisms independent of osteocalcin and glucose metabolism.

49 al associations between circulating forms of osteocalcin and insulin secretion and sensitivity in eld

50 Using mouse models, we found that osteocalcin and LH act in 2 parallel pathways and that o

51 However, associations between osteocalcin and measures of insulin resistance in humans

52 nd markers of bone formation and resorption, osteocalcin and N-telopeptide (NTX), in patients with AN

53 PCR showed a significant increase of mRNA of osteocalcin and osterix at d 14.

54 d serum markers of bone formation, including osteocalcin and procollagen type 1 N propeptide.

55 tudy expands the physiological repertoire of osteocalcin and provides the first evidence that the ske

56 lasts have low circulating undercarboxylated osteocalcin and reduced bone acquisition due to decrease

57 ers such as Runx2, alkaline phosphatase, and osteocalcin and results in decreased culture calcificati

58 Gremlin down-regulation also enhanced osteocalcin and Runx-2 expression, Wnt 3a signaling, and

59 Two-year changes in serum osteocalcin and serum pyridinoline-crosslink fragment of

60 In contrast, elevated carboxylated osteocalcin and total osteocalcin were associated with l

61 Median salivary osteocalcin and tumor necrosis factor-alpha levels were

62 Changes in serum osteocalcin and ucOC are associated with an improvement

63 off system resulted in up-regulation of both osteocalcin and VEGF expression.

64 ditions: bone fragility after estrogen loss (osteocalcin) and arterial calcification linked to cardio

65 tion (bone-specific alkaline phosphatase and osteocalcin) and bone resorption (urinary deoxypyridinol

66 ers of osteoblastic activity, procollagen I, osteocalcin, and alkaline phosphatase.

67 Immunostaining for RUNX2 and osteocalcin, and also histochemical staining with picros

68 c genes, including the alkaline phosphatase, osteocalcin, and bone sialoprotein genes, and temporally

69 genes encoding Runx2, alkaline phosphatase, osteocalcin, and collagen 1alpha1, and mineralization wa

70 , and transcriptional expression of osterix, osteocalcin, and dentin matrix acidic phosphoprotein 1.

71 tor kappa-B ligand (RANKL), osteoprotegerin, osteocalcin, and osteopontin as potential biomarkers of

72 Salivary concentrations of RANKL, osteocalcin, and osteopontin were higher, and osteoprote

73 ps than in the control group, whereas RANKL, osteocalcin, and osteopontin were not related with perio

74 icantly higher plasma levels of osteopontin, osteocalcin, and osteoprotegerin (204%, 148%, and 55%, r

75 ollagen type-I N-terminal propeptide (PINP), osteocalcin, and parathyroid hormone as well as a transi

76 rentiated into mature osteoblasts, expressed osteocalcin, and produced COL1a2 protein, which is absen

77 ressed expression (P </=0.01) of collagen 1, osteocalcin, and Runt-related transcription factor 2 in

78 ine phosphatase, matrix metalloproteases-13, osteocalcin, and runx2, and reduced mineralization.

79 atrix metalloproteinase 13, Indian hedgehog, osteocalcin, and the proapoptotic gene p53.

80 21%) for bone-specific alkaline phosphatase, osteocalcin, and urinary deoxypyridinoline, respectively

81 ear receptor subfamily 4, group A, member 3; osteocalcin; and stanniocalcin 1 (STC1) but not of RUNX2

82 adipocytes showed that picomolar amounts of osteocalcin are sufficient to regulate the expression of

83 n), and bone gamma-carboxyglutamate protein (osteocalcin) are increased by 25(OH)D3 and 1alpha,25-(OH

84 Circulating osteocalcin at 12 months correlated with change in total

85 Associations between each form of osteocalcin at baseline and 3-y change in HOMA-IR were e

86 rtiles of total osteocalcin and carboxylated osteocalcin at baseline had higher baseline HOMA-IR (P =

87 The concentration of carboxylated osteocalcin at baseline was inversely associated with a

88 ding the tightly regulated late stage marker osteocalcin, become constitutively up-regulated in BRM-d

89 The osteoblast-specific secreted molecule osteocalcin behaves as a hormone regulating glucose meta

90 We found that Osteocalcin (Bglap) can be used as an adult tendon-sheat

91 ineralization via transcriptional control of osteocalcin (BGLAP) gene and is the receptor for 1alpha,

92 x (Sp7), Atf4, bone sialoprotein (Ibsp), and osteocalcin (Bglap) without affecting Erk phosphorylatio

93 tin inhibits insulin secretion by decreasing osteocalcin bioactivity, this study illustrates the impo

94 odontogenic differentiation markers such as osteocalcin, bone sialoprotein, and dentin matrix protei

95 tor I without affecting parathyroid hormone, osteocalcin, bone-specific alkaline phosphatase, or tart

96 with systemic BMD loss at the lumbar spine (osteocalcin, bone-turnover biomarker, p = 0.0002) and fe

97 ased expressions of osterix, collagen I, and osteocalcin; but increased trabecular separation, osteoc

98 mRNA expression of osterix, collagen I, and osteocalcin by mesenchymal stem cells at 7 and 14 d of s

99 ited the transactivation activity of ATF4 on osteocalcin by preventing it to bind OSE1, the ATF4 bind

100 how that long-term treatment of WT mice with osteocalcin can significantly weaken the deleterious eff

101 vo the presence of CD163(+)/procollagen-1(+)/osteocalcin(+) cells in the fibrotic and calcified tissu

102 ation, cannot be explained by decarboxylated osteocalcin changes, suggesting existence of other osteo

103 ulator of osteoblast differentiation, and on osteocalcin chromatin.

104 valuated the association between circulating osteocalcin concentrations and insulin secretion and sen

105 not taking oral antidiabetic drugs, baseline osteocalcin concentrations were positively associated wi

106 After treatment, total osteocalcin concentrations were similar at 6 and 12 mo.

107 postnatal mature osteoblasts by crossing Oc (osteocalcin)-Cre mice with floxed Pkd1 (Pkd1(flox/m1Bei)

108 In contrast, in vivo excision of Dicer by Osteocalcin-Cre in mature osteoblasts generated a viable

109 Rb1 using Prx1-Cre, Collagen-1alpha1-Cre and Osteocalcin-Cre to transform undifferentiated mesenchyme

110 ese receptors in osteoblasts and osteocytes (osteocalcin-Cre).

111 rom a HFD and the involvement of insulin and osteocalcin cross-talk in glucose intolerance.

112 how here that the osteoblast-derived hormone osteocalcin crosses the blood-brain barrier, binds to ne

113 ition to these postnatal functions, maternal osteocalcin crosses the placenta during pregnancy and pr

114 Serum bone-specific alkaline phosphatase and osteocalcin decreased on paricalcitol therapy only and s

115 Interestingly, Osteocalcin-deficient mice exhibit increased levels of l

116 of TC-PTP promotes insulin sensitivity in an osteocalcin-dependent manner.

117 The acidic (acidic osteocalcin-derived peptide (OSC)) and amidic (amidic os

118 in-derived peptide (OSC)) and amidic (amidic osteocalcin-derived peptide (OSN)) forms of this sequenc

119 ition rate (MAR) and expression of Runx2-II, Osteocalcin, Dmp1, and Phex.

120 oprotein (DSP), dentin matrix protein-1, and osteocalcin during a phase of reduced matrix metalloprot

121 nduced bone phenotype involves bone-resident osteocalcin-expressing (Ocn(+)) osteoblastic cells.

122 t metabolic homeostasis was due to increased osteocalcin expression and decreased expression of Esp,

123 eoblasts controls osteoblast development and osteocalcin expression by suppressing the Runx2 inhibito

124 the increase in mineral apposition rate and osteocalcin expression detected in vivo.

125 i-IGF1 antibody decreased Runx2 activity and osteocalcin expression in osteoblasts.

126 dulates IGF1/insulin-dependent regulation of osteocalcin expression in osteoblasts.

127 l calvarial cells and that osteoblast marker osteocalcin expression was absent.

128 At the protein level, osteocalcin expression was induced only in the DPSCs on

129 Osteoid formation and osteocalcin expression were described on the alveolar bo

130 BMP-2-induced alkaline phosphatase activity, osteocalcin expression, and SMAD activation.

131 ssed in proliferating osteoblasts and blocks osteocalcin expression.

132 The osteoblast-secreted molecule osteocalcin favors insulin secretion, but how this funct

133 tive marker) greater than 0.311 ng/ml, serum osteocalcin (formative marker) greater than 13.2 ng/ml,

134 staining and immunohistochemistry of GFP and osteocalcin further indicated that the grafted hBMSCs, n

135 s Runx2 activity and expression of the mouse osteocalcin gene 2 (Bglap2) in osteoblasts in vitro.

136 ing sequence in the proximal promoter of the osteocalcin gene.

137 iption factor complex to the promoter of the osteocalcin gene.

138 ng osteoblast (OB)-derived undercarboxylated osteocalcin (Glu-OCN) and pancreatic beta-cell insulin;

139 to the developmental period and establishes osteocalcin/Gprc6a signaling as a major regulator of bet

140 Hence, the loss of osteocalcin/Gprc6a signaling has a profound effect on be

141 Osteocalcin has been related to insulin secretion in exp

142 The elevated levels of osteocalcin, IL-10, GM-CSF, and decreased levels of MCP-

143 Osteocalcin immunohistochemistry in tumors correlated we

144 s and that TRPS1 regulates the expression of osteocalcin in both cell types.

145 e-formation markers alkaline phosphatase and osteocalcin in D2J mice.

146 To determine the importance of osteocalcin in humans, we analyzed a cohort of patients

147 calcified marrow, and elevated expression of osteocalcin in the osteoblasts localized in necrotic reg

148 Bone-derived osteocalcin, in its undercarboxylated, hormonal form, re

149 collagen 1alpha1, alkaline phosphatase, and osteocalcin, in osteoblasts and PDL cells cultured on EM

150 s glucose intolerance in ob/ob mice, whereas Osteocalcin inactivation halves their hyperinsulinemia.

151 ing expression of the phosphatase catalyzing osteocalcin inactivation.

152 In weight-recovered subjects with AN, osteocalcin increased (from 8.0 +/- 3.05 to 11.2 +/- 6.5

153 alpha5, alpha v, beta3, type-I collagen, or osteocalcin, increased on SLA and modSLA at 6 days.

154 This study reveals that the skeleton via osteocalcin influences cognition and contributes to the

155 Osteocalcin is an osteoblast-specific peptide that is re

156 al studies indicate that high uncarboxylated osteocalcin is associated with reduced insulin resistanc

157 The skeletal protein osteocalcin is gamma-carboxylated by vitamin K.

158 evidence that the osteoblast-derived peptide osteocalcin is one of the drivers of the metabolic deran

159 one in humans, but the endocrine function of osteocalcin is unclear.

160 gnificant increase in OB number, serum human osteocalcin level, and trabecular bone.

161 ne-forming sites for 6 weeks increased serum osteocalcin levels and improved long bone mass and micro

162 In addition, serum osteocalcin levels and mRNA expression levels of type I

163 Additionally, there is growing evidence that osteocalcin levels are a reliable marker of insulin secr

164 tion and mineral apposition rates as well as osteocalcin levels were increased in Lef1DeltaN transgen

165 compared with age-matched controls, whereas osteocalcin levels were normal.

166 Elevated osteocalcin levels were not detected in DEX-treated mice

167 Some of the osteocalcin-lineage-derived osteosarcomas were among the

168 e knockouts of 5 less critical VKD proteins [osteocalcin, matrix Gla protein (Mgp), growth arrest spe

169 ose metabolism and fat mass and suggest that osteocalcin may be of value in the treatment of metaboli

170 defects and learning and memory deficits of Osteocalcin(-/-) mice is determined by the maternal geno

171 ale fertility in the mouse and suggests that osteocalcin modulates reproductive function in humans.

172 type, and delivering osteocalcin to pregnant Osteocalcin(-/-) mothers rescues these abnormalities in

173 Runx2-dependent transcriptional activity and osteocalcin mRNA expression and Bglap2 promoter activity

174 n in alkaline phosphatase (ALP) activity and osteocalcin mRNA expression was observed in p85alpha(-/-

175 ining osteopontin(+) cells were reduced, and osteocalcin mRNA in CD45(-) marrow cells was diminished.

176 decreased alkaline phosphatase activity and osteocalcin mRNA levels.

177 in alkaline phosphatase activity, Runx-2 and osteocalcin mRNAs, and absence of mineralized matrix for

178 as Runx2, Osterix, DMP1, Bone sialoprotein, Osteocalcin, NFATc1, and Schnurri-2, which have been imp

179 Osteocalcin (OC) and matrix Gla protein (MGP) are consid

180 ineral aggregates and two adjacent proteins, osteocalcin (OC) and osteopontin (OPN).

181 R-138 with a predicted targeting site on the osteocalcin (OC) promoter resulted in a 3.7-fold reducti

182 iption factor 2, alkaline phosphatase (ALP), osteocalcin (OC), and collagen1alpha1 (COL1A1), and mine

183 ar phosphoglycoprotein (MEPE); bone markers: osteocalcin (OC), core-binding factor alpha 1 (CBFalpha1

184 vated Men1 in mature osteoblasts by crossing osteocalcin (OC)-Cre mice with floxed Men1 (Men1(f/f)) m

185 ints with active disease had lower levels of osteocalcin (OC).

186 PN) expression, whereas it decreased that of osteocalcin (OC).

187 nder the control of the osterix (Osx-Cre) or osteocalcin (Oc-Cre) promoters to generate Osx-Cre(+/-);

188 is factor [TNF]-alpha), and bone metabolism (osteocalcin [OC], carboxy-terminal collagen crosslinks [

189 iption of the alkaline phosphatase (ALP) and osteocalcin (OCL) gene, leading to less ALP activity and

190 (OCL) gene, leading to less ALP activity and osteocalcin (OCL) production.

191 c beta-cell insulin; in turn, insulin favors osteocalcin (OCN) bioactivity.

192 ntaining transcription factor that activates osteocalcin (Ocn) in osteoblasts and indian hedgehog (Ih

193 Osteocalcin (OCN) is an osteoblast-derived hormone favor

194 Osteocalcin (OCN) is an osteoblast-derived hormone that

195 That osteocalcin (OCN) is necessary for hippocampal-dependent

196 ctor 2 (RunX2), bone sialoprotein (BSP), and osteocalcin (OCN) messenger RNA (mRNA), was evaluated us

197 filament protein, suppresses ATF4-dependent osteocalcin (Ocn) transcription and osteoblast different

198 ear antigen (PCNA), bone sialoprotein (BSP), osteocalcin (OCN), and tartrate-resistant acid phosphata

199 ort that specific deletion of bone-producing osteocalcin (Ocn)-expressing cells in vivo markedly redu

200 ied by staining for the osteoblastic marker, osteocalcin (OCN).

201 ial progenitor (CD34, KDR) and osteoblastic (osteocalcin [OCN]) cell surface markers.

202 TCP; Hertwig's epithelial root sheath, HERS; osteocalcin, OCN; periodontal ligament, PDL; periodontal

203 Here, we ask two questions: is the action of osteocalcin on beta cells and adipocytes elicited by the

204 proteomic analysis of proteins bound to the osteocalcin OSE2 sequence of the mouse osteocalcin promo

205 B-cell deficient mice had similar amounts of osteocalcin(+) osteoblast bone modeling surface.

206 The expressions of alkaline phosphatase, osteocalcin, osteonectin, and osteopontin were analyzed

207 001) downregulation of alkaline phosphatase, osteocalcin, osteonectin/osteopontin, and in vitro miner

208 x2-II (Runt-related transcription factor 2), osteocalcin, osteopontin, and bone sialoprotein, were re

209 Salivary levels of RANKL, osteoprotegerin, osteocalcin, osteopontin, and serum glycosylated hemoglo

210 BMP2 was a potent inducer of osteocalcin/osteopontin (statistically significant at P

211 and osteopontin but decreased expression of osteocalcin, osteoprotegerin (mRNA and protein), and sma

212 ohistochemical analyses for the detection of osteocalcin, osteoprotegerin, receptor activator of nucl

213 of osteoblast-related genes such as Col1a1, osteocalcin, osterix and Runx2 as well as increased mine

214 ver biomarker, p = 0.0002) and femoral neck (osteocalcin p = 0.0025).

215 NP diet increased C-terminal telopeptide and osteocalcin (P </= 0.001 for each) despite hypercalciuri

216 on (alkaline phosphatase activity, P < 0.01; osteocalcin, P < 0.05).

217 s reveal that the osteoblast-derived hormone osteocalcin performs this endocrine function.

218 Osteocalcin positivity in XG groups was higher than in c

219 e metabolism markers (osteoprotegerin [OPG], osteocalcin, procollagen type I N-terminal propeptide, a

220 vels in the lowest tertile, higher levels of osteocalcin, procollagen type-1 N-terminal propeptide, a

221 ss and a value in the upper two tertiles for osteocalcin, procollagen type-1 N-terminal propeptide, o

222 Osteocalcin, produced by osteoblasts or released from mi

223 es osteoblast differentiation and stimulates osteocalcin production, which in turn regulates insulin

224 e osteoblastogenesis and subsequent impaired osteocalcin production.

225 mothers rescues these abnormalities in their Osteocalcin(-/-) progeny.

226 t (Cre-PhexDeltaflox/y mice) and conditional osteocalcin-promoted (OC-promoted) Phex inactivation in

227 amma together with ATF4 and Runx2 stimulates osteocalcin promoter activity and endogenous mRNA expres

228 hromatin immunoprecipitation analysis of the osteocalcin promoter as a model for the behavior of the

229 paired-related homeobox gene enhancer or the osteocalcin promoter direct Cre recombinase expression t

230 o the osteocalcin OSE2 sequence of the mouse osteocalcin promoter identified TRPS1 as a regulator of

231 nstrate that the recruitment of Runx2 to the osteocalcin promoter in response to FGF2 treatment is dr

232 ere we show that TRPS1 can directly bind the osteocalcin promoter in the presence or absence of Runx2

233 FIIA gamma is recruited to the region of the osteocalcin promoter previously shown to bind Runx2 and

234 ressing Cre recombinase, driven by the human osteocalcin promoter, were crossed with homozygous mice

235 t to bind OSE1, the ATF4 binding site on the osteocalcin promoter.

236 g sequence abrogates binding of TRPS1 to the osteocalcin promoter.

237 xpressing Nov under the control of the human osteocalcin promoter.

238 the Cre recombinase under the control of the osteocalcin promoter.

239 The osteoblast-derived hormone osteocalcin promotes testosterone biosynthesis in the mo

240 ndeed, chromatin immunoprecipitations of the osteocalcin proximal promoter with antibodies against Ru

241 (mean tissue/ BACKGROUND: =0.65; P=0.04) and osteocalcin (r=0.68; P=0.03) immunohistochemistry.

242 greater than 13.2 ng/ml, and beta-crosslaps/osteocalcin ratio greater than 0.024.

243 teocalcin that lead to downregulation of the osteocalcin receptor and desensitization of the beta cel

244 High serum uncarboxylated osteocalcin reflects low vitamin K status.

245 of the molecule, and more importantly, does osteocalcin regulate energy metabolism in WT mice?

246 expressed in the Leydig cells of the testes, osteocalcin regulates in a CREB-dependent manner the exp

247 in or siRNA-mediated knockdown abrogates the osteocalcin response to FGF2.

248 e of carbonated apatite and the bone protein osteocalcin reveal the presence of protein-bound and fre

249 tase activity and expression of osteopontin, osteocalcin, Runx2/Cbfa1, Osterix, and Notch1 despite no

250 In vivo the same difference exists in osteocalcin's ability to regulate glucose metabolism on

251 s raise the question of whether LH regulates osteocalcin's reproductive effects.

252 ake measurements on a commercially available osteocalcin sandwich ELISA kit.

253 associated with increased undercarboxylated osteocalcin secretion and altered JNK/IRS1/Akt insulin s

254 timulation of alkaline phosphatase activity, osteocalcin secretion and osteoblast mineralization.

255 n and LH act in 2 parallel pathways and that osteocalcin-stimulated testosterone synthesis is positiv

256 significantly attenuated the suppression of osteocalcin synthesis and prevented the development of i

257 also suppress osteoblast function, including osteocalcin synthesis.

258 from chronic elevations in undercarboxylated osteocalcin that lead to downregulation of the osteocalc

259 voring glucose metabolism through a hormone, osteocalcin, that becomes active once uncarboxylated.

260 n signals in osteoblasts activate a hormone, osteocalcin, that promotes glucose metabolism.

261 in circulating levels of the active form of osteocalcin, thereby decreasing insulin sensitivity in s

262 sion of both carboxylated and uncarboxylated osteocalcin through gene therapy, which additionally led

263 cription factors to suppress the activity of osteocalcin through up-regulating expression of the phos

264 as undercarboxylated forms of factor II and osteocalcin to assess tissue and functional status, resp

265 3 (Cx43), in the transcriptional response of osteocalcin to fibroblast growth factor 2 (FGF2) in MC3T

266 ned by the maternal genotype, and delivering osteocalcin to pregnant Osteocalcin(-/-) mothers rescues

267 This study extends the endocrine role of osteocalcin to the developmental period and establishes

268 al associations between circulating forms of osteocalcin (total, uncarboxylated, and carboxylated) an

269 trabecular number of femur and lumbar, serum osteocalcin, total calcium, intact parathyroid hormone,

270 enriched transcription factor that regulates osteocalcin transcription and osteoblast terminal differ

271 by small interfering RNA induced endogenous osteocalcin transcription in immature osteoblasts.

272 promoter identified TRPS1 as a regulator of osteocalcin transcription.

273 ferase reporter assays, we identify that the osteocalcin transcriptional response to FGF2 is markedly

274 ALPL expression and activity and suppressed osteocalcin transcripts in cells from male mice only.

275 amin D [25(OH)D], parathyroid hormone (PTH), osteocalcin, type I collagen C-telopeptide, hormones, an

276 Under-gamma-carboxylated osteocalcin (ucOC) increases insulin secretion and decre

277 ne and serum percentage of undercarboxylated osteocalcin (%ucOC)] and IL-6, osteoprotegerin, and C-re

278 ation of the placebo or phylloquinone, total osteocalcin, ucOC, glucose, and insulin concentrations a

279 Total serum osteocalcin, ucOC, glucose, and insulin concentrations w

280 r, anti-IGF1 or anti-IGF1R blocked Runx2 and osteocalcin upregulation in OBs cocultured with MVNP-exp

281 Runt-related transcription factor 2 (Runx2), osteocalcin, Vega-a, and platelet endothelial cell adhes

282 the symptomatic vs asymptomatic group, while osteocalcin was higher in asymptomatic patients with sta

283 Lower circulating uncarboxylated osteocalcin was not associated with higher HOMA-IR at ba

284 In older adults, circulating uncarboxylated osteocalcin was not associated with insulin resistance.

285 K-ligand (RANKL), osteoprotegerin (OPG), and osteocalcin was performed.

286 ted expression of type I collagen alpha1 and osteocalcin was reduced in bone of Osx::CXCR4(fl/fl) mic

287 13 amino acids present in the first helix of osteocalcin was selected based on its calcium binding ab

288 elevated carboxylated osteocalcin and total osteocalcin were associated with lower insulin resistanc

289 rnover biomarkers N-terminal telopeptide and osteocalcin were not changed by the interventions; howev

290 near regression analysis, increases in serum osteocalcin were significantly associated with an increa

291 Tartrate-resistant acid phosphatase and osteocalcin were used to identify osteoclastic and osteo

292 nd mRNA for Runx2 and its downstream target, osteocalcin, were also increased in miR-433 decoy mouse

293 osteopontin and matrix Gla protein, but not osteocalcin, were concomitant to the level of hepatic ex

294 s, so-called 'thermostable' proteins such as osteocalcin which has been proposed as a ideal target to

295 ing reduce serum levels of undercarboxylated osteocalcin, which in turn exacerbate insulin resistance

296 on of Esp, a gene inhibiting the activity of osteocalcin, which is an insulin secretagogue.

297 In particular, the peptide hormone osteocalcin, which is made by bone and fat, appears to p

298 Recombinant osteocalcin, which is reciprocally regulated with Saa3 a

299 at secretes at least two hormones, FGF23 and osteocalcin, which regulate kidney function and glucose

300 e have increased serum levels of insulin and osteocalcin with decreased leptin levels.